Mobile

An eight-week double-blind, multi-center, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren 75mg, 150mg and 300mg in elderly patients with essential...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-001305-42

An eight-week double-blind, multi-center, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren 75mg, 150mg and 300mg in elderly patients with essential hypertension when given with a light meal

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Confirm the efficacy of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal by testing the hypothesis of superior reduction in mean sitting systolic blood pressure (msSBP) from baseline to end of study when compared to placebo.

Critère d'inclusion

  • Hypertension

Liens